KUALA LUMPUR, Nov 30 (Bernama) -- BioSkryb Genomics, a company transforming single-cell molecular discovery and analysis, has appointed Dr Ram Laxman, as Chief Commercial Officer.
Dr Laxman will lead sales and support, commercial strategy and operations, and marketing as BioSkryb continues to scale its global presence, according to BioSkryb Genomics in a statement.
He brings strong executive leadership experience and an extensive track record of building and scaling businesses at companies like 10x Genomics, Pacific Biosciences, and Illumina.
“We are excited to welcome Ram to our leadership team and know that his deep expertise in establishing and growing a solid presence for some of the most successful companies in the genomics space will allow us to exponentially increase our international footprint.
“This year, BioSkryb has experienced a strong growth surge in North America where our focus has been, and with Ram on board, we are poised to drive significant growth for the company and expand the footprint of our industry leading single-cell products globally in the years to come,” said its Chief Executive Officer, Suresh Pisharody.
Meanwhile, Dr Laxman said he is looking forward to scaling BioSkryb’s presence across the globe and driving the company’s commercial pipeline to bring its technology to new users.
Dr Laxman joins BioSkryb from 10x Genomics, where he served as the President and General Manager, APAC, and as the company’s first hire in Asia Pacific (APAC), he was instrumental in building 10x Genomics’ presence in the region.
Before 10x Genomics, he was part of the very early commercial teams at Illumina and Pacific Biosciences. Dr Laxman holds a Doctor of Philosophy (PhD) in molecular biology and served as a postdoctoral fellow with the eminent Professor Daniel Koshland at the University of California, Berkeley.
His predecessor, Reagan Tully, has been appointed Chief Business Officer of the organisation, leading corporate, business, and market development functions, focused on expansion and adoption of the technology through key partnerships and collaborations across the industry.
These appointments reflect BioSkryb’s continued momentum in advancing single-cell analysis, including the launch of ResolveOME, a revolutionary multiomic solution, and the first-of-its-kind BaseJumper platform for multimodal bioinformatics analysis.
-- BERNAMA
No comments:
Post a Comment